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Abstract  
BACKGROUND: Cardiac biomarkers are often elevated in dialysis patients showing the presence 
of left ventricular dysfunction. The aim of the study is to establish the plasma levels of high-
sensitivity cardiac troponin T (hs TnT), precursor of B-natriuretic peptide (NT-proBNP) and high 
sensitivity C-reactive protein (hs CRP) and their relation to the presence of left ventricular 
hypertrophy (LVH) in patients undergoing hemodialysis without signs of acute coronary syndrome 
or heart failure.  
MATERIAL AND METHODS: We studied 48 patients - 26 men and 22 women. Pre and 
postdialysis levels of hs cTnT, NT-proBNP and hs CRP were measured at week interim procedure. 
Patients were divided in two groups according to the presence of echocardiographic evidence of 
LVH - gr A - 40 patients (with LVH), and gr B - 8 patients (without LVH).  
RESULTS: In the whole group of patients was found elevated predialysis levels of all three 
biomarkers with significant increase (p < 0.05) after dialysis with low-flux dialyzers. Predialysis 
values of NT-proBNP show moderate positive correlation with hs cTnT (r = 0.47) and weaker with 
hs CRP (r = 0.163). Such dependence is observed in postdialysis values of these biomarkers. 
There is a strong positive correlation between the pre and postdialysis levels: for hs cTnT (r = 
0.966), for NT-proBNP (r = 0.918) and for hs CRP (r = 0.859). It was found a significant difference 
in the mean values of hs cTnT in gr. A and gr. B (0.07 ± 0.01 versus 0.03 ± 0.01 ng /mL, p < 0.05) 
and NT-proBNP (15,605.8 ± 2,072.5 versus 2,745.5 ± 533.55 pg /mL, p < 0.05). Not find a 
significant difference in hs CRP in both groups.  
CONCLUSIONS: The results indicate the relationship of the studied cardiac biomarkers with LVH in 
asymptomatic patients undergoing hemodialysis treatment. 
 
 
 
 
Introduction 
 
Cardiorenal syndrome type 4 often manifests 
itself with patients undergoing hemodialysis treatment 
in stage 5 HD on chronic kidney disease (CKD). It is 
characterized by primary CKD, associated with left 
ventricular (LV) damage, including left ventricular 
hypertrophy (LVH), systolic and diastolic dysfunction 
and congestive heart failure [1]. 
Echocardiographically-proven LV hypertrophy is 
detected in 60-75% of patients starting renal 
replacement therapy and in 60-90% of those on 
regular dialysis treatment [2, 3] LVH is considered an 
independent risk factor for cardiovascular mortality in 
this population [4-6]. Pathophysiologic factors involved 
in LVH of CKD and ESRD patients have generally 
been divided into 3 categories [7-9]: (1) related to 
afterload, (2) related to preload, and (3) not related to 
afterload or preload. The ones in the first category are 
represented by an increase in systemic arterial 
resistance, elevated arterial blood pressure, and 
reduced large-vessel compliance [7-9] related in part 
to aortic ‘calcification', which is typical in CKD 
patients; all these factors result in myocardial cell 
thickening and concentric LV remodeling often 
together with activation of the intracardiac renin-
angiotensin system [9, 10]. Additional roles have 
inadequate activation of the renin-angiotensin-
aldosterone system, hypervolemia, anemia, oxidative 
stress and inflammation [4, 11, 12]. Oxidative stress 
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and xanthine oxidase activation as well as the 
phosphodiesterase-5 pathway may also be involved in 
the development of LVH [13]. Among the preload-
related factors, the role of intravascular volume 
expansion (salt and fluid loading) has to be 
underlined, as well as secondary anemia and the 
presence of arterovenous fistulas [14, 15], resulting in 
myocardial cell lengthening and eccentric or 
asymmetric LV remodeling. Both afterload- and 
preload-related factors operate with additive and 
synergistic effects. As a result, myocardial 
hypertrophy induces the activation of cellular apoptotic 
signals and activates metabolic pathways able to 
increase extracellular matrix production up to fibrosis 
[16, 17]. Fibrosis leads to progressive impairment in 
contractility with stiffening of the myocardial wall, 
systolic and diastolic dysfunction, dilated 
cardiomyopathy and congestive heart failure [18]. 
Renin-angiotensin-aldosterone system activation 
induces hyperaldosteronemia promoting cardiac 
fibrosis through the generation of signals leading to 
profibrotic transforming growth factor production [19]. 
The LVH can also be promoted by iron and/or 
erythropoietin [20] or vitamin D deficiency [21]. The 
presence of arterovenous fistulas can contribute to the 
development of LVH because of excess blood flow 
that increases the myocardial workload [22]. 
Persistent inflammatory condition is recognized as an 
important risk factor for the development of 
cardiovascular complications in this group of patients. 
Their levels of C- reactive protein (CRP) correlate 
positively with LVH [23]. Cardiac biomarkers reflect LV 
structure and function and are essential for early 
diagnosis of heart failure. In recent years, natriuretic 
peptides, in particular the B-type natriuretic peptide 
(BNP), are used in screening for the risk of 
cardiovascular events in the general population [24-
27]. BNP is synthesized in ventricular myocytes, 
undergoing intracellular metabolism to prohormone 
(proBNP), which is then fragmented into activated (C-
terminal) and inactive (N-terminal) proBNP. In 
practice, NT-proBNP is tested more often because of 
its longer half-life in the circulation (60-120 min) than 
that of BNP, which is 23 minutes long [24]. BNP and 
NT proBNP are biological markers of left ventricular 
dysfunction [28]. Another biomarker is cardiac 
troponin T (cTnT), which is released into the 
circulation and increases sharply if irreversible 
damage to the heart muscle exists [29]. There are 
other reasons for the presence of cTnT. These are 
myocardial damage due to high pressure in the left 
ventricular wall in hypertrophy, acute or chronic 
volume overload, microvascular lesions, "quiet" 
subclinical myocardial ischemia fibrosis and necrosis. 
In hemodialysis patients, these conditions are very 
common [30]. 
Objectives of the study are: -to determine 
plasma levels of high-sensitivity cardiac troponin T (hs 
sTnT), NT-proBNP and high sensitivity C-reactive 
protein (hs CRP) and their changes during 
hemodialysis; and -to link LVH and cardiac 
biomarkers in patients undergoing hemodialysis 
without signs of acute coronary syndrome or heart 
failure. 
 
 
Material and Methods 
 
Forty eight patients were studied (26 men and 
22 women) undergoing a standard 4-hour bicarbonate 
dialysis three times a week, over three months. All 
patients used low-flux dialyzers with polysulfone 
membranes. The adequacy of dialysis was evaluated 
by URR%. Clinically they are hemodynamically stable 
(in sinus rhythm, with values of BP below 150/90, 
without manifestation of hypertensive crisis, without 
clinical manifestations of hypotensive reactions), with 
no evidence of acute coronary syndrome or heart 
failure in the previous two months. Patients with a 
diagnosis of cancer, autoimmune diseases and signs 
of active inflammation were excluded.  
Determined pre- and post-dialysis are levels 
of hs sTnT, NT-proBNP and hs CRP immediately 
before the interim procedure for the week. hs sTnT 
and NT-proBNP were analyzed with Elecsys 2010 
immunoassay reagents of Roshe Diagnostics. NT-
proBNP was reported in pg/mL. The values of NT-
proBNP > 125 pg/mL are considered a threshold 
taken from the manufacturer's package insert above 
which it can be assumed cardiac dysfunction related 
to an increased risk of cardiac events (myocardial 
infarction, heart failure, death). The above hs sTnT 
reference value is specified by the manufacturer 
through testing of 533 healthy subjects (99th 
percentile of healthy) and 0.014 ng/mL. hsCRP was 
investigated by biochemical analyzer Beckman 
Coulter AU 480 by immunoturbidimetric method with 
reagents Roshe Diagnostics and has an upper 
reference value of 1.0 mg/L. Patients were divided 
into two groups according to the presence of the 
echocardiography evidence of LVH - group A (with 
LVH) and group B (without LVH). Echocardiography 
was performed on non-dialysis day, 24 hours after the 
last hemodialysis, with PHILIPS XE 11.  
Left ventricular structure was evaluated by 2M 
echograph mode. LV mass was corrected for body 
surface area and presented as LV mass index (LVMI). 
The criteria for LVH are LVMI > 115 g/m
2
 in men and 
LVMI > 95 g/m
2
 in women. Compared were the 
thickness of the free wall of the LV (LVPW d), the 
thickness of the interventricular septum (IVS d) in 
diastole, the ejection fraction (EF%) and fraction of 
shortening (FS%) in both groups of patients. All 
patients were in sinus rhythm with no abnormalities in 
the kinetics of the LV wall and without severe valvular 
heart damage. 
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To process the statistical data was used R-
Project software version 3.1.1. Descriptive statistics 
was presented and statistical results are reported in 
mean ± standard error of the average. All parameters 
were tested for normal distribution using the test of 
Shapiro-Wilk. The relationship between performances 
was recorded using linear regression. Statistically 
significant difference was accepted at p < 0.05. 
 
 
Results 
 
The main demographic and clinical 
characteristics of the study group of 48 patients were: 
26 men and 22 women; mean age 53.04 ± 2.24 years; 
the average duration of hemodialysis treatment 54 ± 
7.74 months; the average URR% - 64.8%. In 17 
patients the primary renal disease leading to CKD is 
chronic tubulointerstitial nephritis, in 14 - chronic 
glomerulonephritis, in 9 - diabetic nephropathy, in 5 - 
polycystic kidney disease and three - other disabilities 
(congenital anomalies, obstructive nephropathy). 
Table 1: Values of cardiac biomarkers before and after the 
dialysis procedure 
Biomarker 
Predialytic 
values of 
biomarkers mean 
± sem 
Postdialytic 
values of 
biomarkers mean 
± sem 
р r 
hs сTnT (ng/mL) 0.06 ± 0.01 0.07 ± 0.01 р < 0.001 0.966 
NT-proBNP (pg/mL) 13,462 ± 1,862 15,279 ± 1,895 р < 0.001 0.918 
hs CRP (mg/L) 16.30 ± 4.19 15.44 ± 3.73  р < 0.05 0.859 
 
In all of the patients were found elevated 
mean values of cardiac biomarkers and hs CRP, both 
before and after the dialysis procedure. Post-dialysis 
levels of hs cTnT and NT-proBNP were significantly 
higher (p < 0.001) while hs CRP significantly lower (p 
< 0.05). A statistically significant difference was 
registered as well as a very high correlation between 
pre- and post-dialysis levels of markers tested: in hs 
cTnT (r = 0.966), in NT-proBNP (r = 0.918) and hs 
CRP (r = 0.859) – the statistical analysis in both 
groups of patients is based on predialytic values. 
(Table 1) Predialytic indicators studied in men and 
women showed significant difference in hs cTnT (0.07 
± 0.02 compared to 0.06 ± 0.01; p <0.05). The 
remaining two biomarkers are higher in women, but 
the difference was not statistically significant (Table 
2).  
Table 2: Predialytic values of cardiac biomarkers in men and 
women 
Value Men Women р 
hs TnT 0.07 ± 0.02 0.06  ± 0.01 р < 0.05 
NT-proBNP 12,845  ± 2,624 14,192  ± 2,683 p - NS 
hs CRP 15.21  ± 6.35 17.65  ± 5.29 p - NS 
 
Predialytic values of NT-proBNP in all 
investigated patients showed moderate correlation 
with hs cTnT (r = 0.47) and a weaker one with hs CRP 
(r = 0.163). Such dependence is observed in the post-
dialysis values of these parameters, respectively 
compared hs cTnT (r = 0.482) and hs CRP (r = 0.19) 
(Table 3). 
Table 3: Correlations between the values of NT-proBNP with hs 
cTnT and hs CRP - before and after hemodialysis 
Predialytic values 
of biomarkers 
Correlation 
coefficient (r) 
Postdialytic 
values of 
biomarkers 
Correlation 
coefficient (r) 
hs cTn T 0.47 hs cTn T 0.482 
hs CRP 0.163 hs CRP 0.19 
 
Forty patients from group A (with LVH) take 
part in the echocardiographic study, while in group B 
(without LVH) - 8 patients participate: LVH was 
present in 83% of the study group. Table 4 shows the 
ultrasound data of the two groups. Patients with LVH 
had significantly higher values of LVMI, LVPW and 
IVS, while indicators of systolic function EF% and 
FS% showed no differences in both groups. 
Table 4: Echocardiographic parameters in patients with and 
without LVH 
Echocardiographic 
parameter 
Value 
mean±sem 
р 
 GroupА with LVH Group В without LVH  
LVMI g/m
2
 151.97 ± 4.23 94.24 ± 5.27 p<0.005 
LVPW d /sm 1.19 ± 0.02 0.94 ± 0.06 p<0.005 
IVS d /sm 1.34 ± 0.03 1.08 ± 0.05 p<0.005 
EF% 62.8 ± 1.58 68.5 ± 3.29 p - NS 
FS% 35.2 ± 1.17 38.4 ± 2.4 p - NS 
 
With all patients studied, levels of NT-proBNP 
were significantly higher than the threshold values. In 
group A the average is 15,605.8 ± 2,072.5 pg/mL with 
77.5% having values above the limit of chronic heart 
failure functional class I NYHA (3,410 pg/mL). In 
group B the recorded average value of this biomarker 
is 2,745.5 ± 533.6 pg/mL, with only 25% of the 
patients with the values were above the threshold for 
chronic heart failure functional class I NYHA. A 
significant difference was found in the mean values of 
hs cTnT between patients in group A and B (0.07 ± 
0.01 ng/mL compared to 0.03 ± 0.01 ng/mL, p <0.05) 
and NT- proBNP (15,605.8 ± 2,072.5 compared to 
2,745.5 ± 533.6 pg/mL, p < 0.05) before hemodialysis. 
Although the values of hs CRP were higher in patients 
with LVH, there wasn’t a significant difference in this 
indicator in both groups. A similar dependence was 
observed in post-dialysis values of biomarkers (Table 
5). 
Table 5: Pre- and post-dialysis values of cardiac biomarkers in 
the two groups of patients 
 
GroupА 
with LVH 
Group В 
without LVH 
р 
Predialytic values of 
biomarkers 
   
hs сTnT 0.07 ± 0.01 0.03 ± 0.01 p < 0.05 
NT-proBNP 15,605.8 ± 2,072.5 2,745.5 ± 533.6 p < 0.005 
hs CRP 17.87 ± 4.85 7.35 ± 4.05 p=0.054 
Postdialytic values of 
biomarkers 
   
hs сTnT 0.08 ± 0.01 0.04 ± 0.01 p < 0.05 
NT-proBNP 16,807.7 ± 2,099 7,635 ± 3,455.9 p < 0.05 
hs CRP 16.66 ± 4.39 9.5 ± 4.59 p  - NS 
 
Statistical analysis established that there was 
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a positive moderate correlation between hs cTnT and 
NT proBNP (r = 0.43). of hs cTnT with hsCRP (r = 
0.61). and a weaker. but also positive correlation 
between NT proBNP and hsCRP (r = 0.10) in patients 
with LVH. In this group there is a positive correlation 
of each of the biomarkers with LVMI. LVPW IVS and it 
is most pronounced compared to the thickness of the 
interventricular septum (Table 6). Three cardiac 
biomarkers showed negative correlation with EF% 
and FS%. 
Table 6: Correlation analysis between cardiac biomarkers and 
echocardiographic parameters in patients with LVH 
 hs cTnT NT proBNP hs CRP LVMI LVPW IVS EF% FS% 
hs cTnT - r=0.43 r=0.61 r=0.23 r=0.28 r=0.46 r= -0.04 r=0.001 
NT-proBNP r=0.43 - r=0.10 r=0.31 r=0.24 r=0.32 r=-0.21 r=-0.21 
hs CRP r=0.61 r=0.10 - r=0.18 r=0.39 r=0.50 r= -0.25 r= -0.08 
 
 
 
Discussion  
 
Our study found a very high prevalence of 
LVH in hemodialysis patients, i.e. 83%. Similar results 
presented by other studies indicate that 75-78% of 
these patients had LVH in stage 5 CKD on HD [31, 
32]. We found a positive correlation of hs CRP with 
ultrasound parameters LVMI. LVPW and IVS (r = 
0.18; r = 0.39; r = 0.50) in group of patients with LVH. 
This, on its own part, defines the essential role of 
inflammation in the development of LVH in patients on 
hemodialysis. Along with hypertension and volume 
overload, systemic inflammatory state may contribute 
to the development of LVH by changing the structure 
and function of vascular smooth muscle cells. leading 
to increased vascular stiffness [33]. On the other 
hand, it is considered that chronic subclinical 
inflammation alters LV structure and geometry by 
disrupting the balance between cell growth and 
apoptosis in cardiac tissue [34]. 
When using a low-flux dialyzers. there was a 
significant increase in the levels of NT-proBNP in all 
investigated patients. Being released into the 
circulation in abnormally high volume, it stretches 
cardiomiofibres. The established increased level after 
an adequate hemodialysis procedure and normal 
hemodynamics, suggests the role of other factors in 
increased plasma levels. Wahl et al [35] reported that 
pre- and post-dialysis levels of NT-proBNP are 
dependent on the type of membrane used during HD. 
High-flux membranes have a higher ultrafiltration rate 
than low-flux membranes. They tend to have larger 
pores, which means that the clearance of NT-proBNP 
with a molecular weight of 8.5 kDa is higher than 
when using low-flux membranes. where the post-
dialysis concentration increased. In our study we 
found that NT proBNP was, to a high degree, 
correlated with some echocardiographic parameters – 
LVMI, LVPW and IVS in group of patients with LVH. 
This biomarker of cardiomyocyte microinjury and 
hemodynamic stress may stimulate fibrosis-related 
mechanisms and facilitate the diagnosis of subclinical 
LV remodelling and LVH in this population. 
hs cTnT values above the 99th percentile in 
healthy frequently found in patients with LVH and 
heart failure in the absence of acute coronary 
syndrome and in patients with CKD and without 
clinical heart disease [36-38]. The mechanism of this 
subclinical myocardial injury with elevated sTnT has 
not yet been elucidated [39]. It is believed that 
stretching and deformation of myocardium in LVH 
impairs the permeability of cardiomyocytes, leading to 
the release of cardiac troponins. On the other hand, 
the increased oxygen demand in hypertrophied LV 
with reduced coronary reserve may cause subclinical 
ischemia with or without macrovascular coronary 
artery disease [39]. Since all patients studied are 
asymptomatic, the established moderately high 
positive correlation between LVMI, LVRW and IVS 
and the values of the cardiac biomarkers suggest that 
their measurement can be used for preclinical 
diagnosis of LVH. 
In conclusion, our data is based on 83% 
incidence of LVH in patients receiving dialysis. Pre- 
and post-dialysis values of cardiac biomarkers and hs 
CRP were increased in all patients just as it is 
manifested in those with LVH. There is a positive. 
moderate correlation between the degree studied 
biomarkers. Cardiac biomarkers correlate well with 
echocardiography parameters showing LVH. The 
study of cardiac biomarkers can be used as a 
screening for the presence of LVH in asymptomatic 
patients treated with hemodialysis. 
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